Dr Dejan Radeski
MB BS FRACP FRCPA
Dr Dejan Radeski is a consultant haematologist with research interests in T-cell lymphoma and post transplant lymphoproliferative disorders.
He is a graduate of the University of Western Australia and trained in Perth and at the Centre for Lymphoid Malignancies, Columbia University, New York.
He is co-chair of T-cell lymphoma network part of the Australian Lymphoma Alliance. He consults out of Sir Charles Gairdner Hospital and Joondalup Health Campus.
Publications
- A unique case of splenic rupture secondary to vaccine-induced immune thrombocytopenia managed with splenic embolization
- Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
- Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation
- Mycosis fungoides and Sézary syndrome: Australian clinical practice statement
- Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
- Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study
- Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia
- Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review
- Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia
- Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia
- Variation in outpatient consultant physician fees in Australia by specialty and state and territory
- Post-transplant lymphoproliferative disorder: a heterogeneous conundrum - response to Weisenburger DD & Gross TG
- Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
- Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
- Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
- Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice
- Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure